Previous Close | 53.25 |
Open | 53.39 |
Bid | 53.81 x 900 |
Ask | 54.72 x 900 |
Day's Range | 53.39 - 54.47 |
52 Week Range | 47.58 - 71.07 |
Volume | |
Avg. Volume | 16,870,439 |
Market Cap | 109.663B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 14.05 |
EPS (TTM) | 3.86 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 2.40 (4.43%) |
Ex-Dividend Date | Apr 04, 2024 |
1y Target Est | 56.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BMY
Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, did not help patients achieve disease remission in a late-stage study. Crohn's is a chronic bowel disease that causes inflammation in the digestive tract, and can lead to diarrhea, abdominal pain, fatigue and weight loss. The drug, ozanimod, was added to the U.S. drugmaker's portfolio through its $74 billion buyout of Celgene in 2019.
PRINCETON, N.J., March 28, 2024--Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint....
PRINCETON, N.J., March 28, 2024--BMS Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderately to Severely Active Crohn’s Disease